Unfortunately, the patient was not eligible for ASCT because of severe bortezomib‐ and thalidomide‐induced neuropathy and JAK2‐mutated myeloproliferative neoplasm with marked splenomegaly. Here, JAK2 is linked to myeloproliferative neoplasm.